EVOQ Therapeutics has entered into a Collaboration and Licence Agreement with Sanofi.

EVOQ Therapeutics与赛诺菲达成了合作和许可协议。

The partnership focuses on advancing EVOQ’s proprietary NanoDisc technology, which aims to restore the body’s natural immune tolerance mechanisms.

该合作专注于推进EVOQ专有的NanoDisc技术，该技术旨在恢复人体的自然免疫耐受机制。

This platform has the potential to develop disease-specific therapies for autoimmune conditions such as coeliac disease, type 1 diabetes, myelin oligodendrocyte glycoprotein (MOG) antibody disease, rheumatoid arthritis, and lupus.

该平台有潜力开发针对自身免疫疾病的特定疗法，例如乳糜泻、1型糖尿病、髓鞘少突胶质细胞糖蛋白（MOG）抗体病、类风湿性关节炎和狼疮。

Existing treatments largely manage symptoms rather than address the root cause — the breakdown of immune tolerance leading to the destruction of healthy tissues.

现有的治疗大多只是控制症状，而不是解决根本原因——免疫耐受的破坏导致健康组织的损伤。

EVOQ’s NanoDisc technology seeks to overcome this by re-establishing immune tolerance to enable curative outcomes.

EVOQ的NanoDisc技术旨在通过重建免疫耐受来克服这一问题，从而实现治愈效果。

EVOQ stands to receive more than USD 500 million in upfront, preclinical, development, and sales milestone payments, along with tiered royalties on future product sales.

EVOQ将获得超过5亿美元的预付款、临床前、开发和销售里程碑付款，以及未来产品销售的阶梯式专利使用费。

Under the agreement, EVOQ and Sanofi will collaborate on research activities, with Sanofi responsible for global development and commercialisation.

根据协议，EVOQ和赛诺菲将合作开展研究活动，赛诺菲负责全球开发和商业化。

Source: prnewswire.com

来源：prnewswire.com